TORONTO, June 28, 2021 /CNW/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND), a health-tech company focused on mental wellness, today announced that Dr. Luca Pani, MD has been appointed as Chief Medical Advisor and will serve on its Mental Health Advisory Council. Dr. Pani joins a global council of thought leaders with unique and diverse expertise in the areas of medicine, athletics, and technology including NFL superstar Richard Sherman and decorated Olympian Michael Phelps.
Dr. Pani served as the Director General of the Italian Medicines Agency (AIFA) for five years and currently sits on several boards including the Committee for Human Medicines (CHMP) and the Scientific Advice Working Party (SAWP) for the European Medicines Agency. He was also elected as the Chair of the EU Telematics Committee overlooking the European Medicines Agency (EMA) databases transition plan.
In his current role, Dr. Pani is a Professor of Pharmacology and Clinical Pharmacology at the University of Modena and Reggio Emilia in Italy and a Professor of Clinical Psychiatry at the University of Miami, USA. He also serves as Vice President for Regulatory Strategy and Market Access Innovation at VeraSci in Durham, NC and the Chief Advisor for the Drug Development Pipeline of Relmada.
"I could not be more excited to help fuel the growth of a company that has great vision and purpose. Mental health and wellness is something that impacts us all universally. Being able to have my background contribute in driving this agenda forward makes great sense and I could not be more proud to partner with the team at Nurosene," said Dr. Pani.
Dr. Pani is a recognized expert in basic and clinical pharmacology with particular emphasis on health technology assessments and is the author of over 180 scientific publications. His deep expertise with large web-based clinical datasets will help to guide Nurosene's innovation efforts and lead the Company's Mental Health Advisory Council as it relates to potential medical solutions in the market.
"We are thrilled to have Dr. Pani lead us through this journey. His deep knowledge and expertise in Clinical Psychiatry and Pharmacology will strengthen our NURO app and be of great value to us as we build our NURO toolbox. Dr Pani will be guiding our research initiatives at Nurosene and we are excited to leverage his extensive experience in working with FDA protocols" said Ranj Bath, CEO of Nurosene.
Nurosene provides individuals with tools and technology that empower them to take control of their mental wellness. Its mission is to build the next generation of better, healthier brains by leveraging technological advancements in AI and machine learning. With its team of experts and partners, Nurosene is positioned at the leading edge of critical research and innovations, striving to disrupt traditional mental wellness treatments. The company is based in Toronto, Ontario.
For more information, visit www.nurosene.com
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect," "likely," "may," "will," "should," "intend," "anticipate," "potential," "proposed", "estimate," and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may," "would," or "will," happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Specifically, this news release contains forward looking statements relating to, among others, activities of the Company's Mental Health Advisory Council, the Company's research activities and Dr. Pani's contributions thereto.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene Final Long Form Prospectus dated May 20, 2021 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Nurosene Health Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2021/28/c4873.html
The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on www.SEDAR.com for important risk disclosures. It’s your money and your responsibility.